Breast Cancer
Conference Coverage
Adjuvant capecitabine found disappointing in TNBC
SAN ANTONIO – A phase 3 trial was negative, showing that adding adjuvant capecitabine to surgery and chemotherapy does not improve survival in...
Conference Coverage
Adjuvant T-DM1 halves HER2-positive invasive breast cancer recurrence
SAN ANTONIO – The 3-year invasive disease-free recurrence was 88.3% for patients with residual disease treated with T-DM1 versus 77.0% with...
Article
Maternal health benefits of breastfeeding
Diseases highly prevalent among women include type 2 diabetes, hypertension, and coronary artery disease, as well as breast, ovarian, and...
Article
Trio of biosimilars have good showing
Article
Elevated liver function tests in a patient on palbociclib and fulvestrant
Article
Symptom burdens related to chemotherapy-induced anemia in stage IV cancer
Conference Coverage
PD-L1 expression best predicts response to atezolizumab + nab-paclitaxel for mTNBC
SAN ANTONIO – IMpassion130 analyses show that PD-L1 expression on tumor-infiltrating immune cells is the best...
Conference Coverage
No boost in OS with addition of capecitabine for early TNBC
SAN ANTONIO – Adding adjuvant capecitabine to surgery and standard chemotherapy did not improve disease-free or overall survival in women with...
Conference Coverage
Similarity of CT-P6 and trastuzumab remain with longer follow-up
The efficacy and cardiac toxicity profile between trastuzumab biosimilar candidate CT-P6 and trastuzumab, as neoadjuvant and then adjuvant therapy...
Conference Coverage
KATHERINE: T-DM1 doubles HER2-positive invasive disease-free survival
SAN ANTONIO – For the primary endpoint of invasive disease-free survival, T-DM1 was associated with a hazard ratio of 0.50.